Vuno Inc
Vuno Inc is a South Korean company specializing in healthcare equipment and technology, providing AI-powered diagnostic and clinical decision support systems to hospitals and healthcare providers.
Business. Vuno Inc is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is listed on the KOSDAQ under the ticker symbol 338220.KQ. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a provider of medical technology products.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Vuno Inc is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is listed on the KOSDAQ under the ticker symbol 338220.KQ. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a provider of medical technology products.
Vuno Inc operates with a capital structure that includes a debt-to-equity ratio of 0.21, indicating a relatively conservative leverage position. The company holds cash and equivalents of KRW 5,554,309,540, but its operating cash flow is negative at KRW -4,675,991,670, and free cash flow is also negative at KRW -5,310,416,030. This suggests that the company is currently not generating sufficient cash from operations to fund its activities or reduce debt.
Profitability metrics show significant challenges for Vuno Inc. The company reported a net loss of KRW -5,779,512,010 and an operating loss of KRW -4,933,322,120. Return on equity (ROE) is -16%, and return on assets (ROA) is -11.47%, both well below the industry median for advanced medical equipment and technology firms. These figures indicate that the company is not generating returns that meet the expectations of its shareholders or asset base.
Geographically, Vuno Inc's revenue is primarily concentrated in South Korea, with no disclosed international segments. The company's business model is centered around its AI diagnostic platform, which is deployed in domestic hospitals. This concentration increases exposure to local economic and regulatory conditions, which could impact revenue stability.
Looking ahead, Vuno Inc is expected to continue facing financial challenges. The company's revenue is projected to remain flat or decline in the current fiscal year, with no significant growth expected in the next fiscal year. This is consistent with the company's historical performance, which has shown declining profitability and increasing losses. Analysts have issued a mean recommendation of 1.00 (strong buy), but this is based on a single strong-buy rating with no buy, hold, sell, or strong-sell ratings, suggesting limited consensus among analysts.
The company's risk profile is characterized by medium liquidity risk and low dilution risk. While the company has a current ratio of 3.05, indicating it can cover its short-term liabilities, its negative operating and free cash flows suggest potential liquidity constraints in the medium term. The risk assessment also notes that net cash is negative after subtracting total debt, which could limit the company's ability to fund operations or invest in growth without external financing.
Recent events and disclosures indicate that Vuno Inc is actively managing its financial position. The company has not issued new shares recently, and there are no indications of imminent dilution. However, the company's continued losses and negative cash flows may necessitate future financing, which could involve issuing new shares or taking on additional debt. The company's capital expenditure of KRW -1,069,531,020 suggests ongoing investment in infrastructure or technology, but the negative sign indicates that these expenditures are not being offset by asset sales or other inflows.
- Vuno Inc is experiencing significant financial losses, with a net loss of KRW -5.78 billion and an operating loss of KRW -4.93 billion.
- The company's debt-to-equity ratio of 0.21 suggests a relatively conservative capital structure, but its negative cash flows raise liquidity concerns.
- Vuno Inc's profitability metrics (ROE of -16% and ROA of -11.47%) are well below industry medians, indicating poor returns on equity and assets.
- The company's revenue is concentrated in South Korea, increasing its exposure to local economic and regulatory conditions.
- Analysts have issued a strong-buy rating, but this is based on a single recommendation, suggesting limited consensus.
- Vuno Inc is expected to continue facing financial challenges in the near term, with no significant growth expected in the next fiscal year.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 278,00 |
| Revenue | —no estimate | —no estimate | 51,9B KRW |
| Operating income | —no estimate | —no estimate | 5,1B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Vuno Inc Market data — financials · 2026-05-26
- Vuno Inc Market data — analyst estimates · 2026-05-26